Taurine deficiency Is a cause of vigabatrin-induced retinal phototoxicity

Annals of Neurology

Volumn 65, Issue 1, 2009, Pages 98-107

  Jammoul, Firas ^a,b   Wang, Qingping ^a,b,c   Nabbout, Rima ^a,d,e   Coriat, Caroline ^a,b   Duboc, Agnès ^a,b   Simonutti, Manuel ^a,b   Dubus, Elisabeth ^a,b,i   Craft, Cheryl M ^f,g   Ye, Wen ^c   Collins, Stephen D ^h   Dulac, Olivier ^a,d,e   Chiron, Catherine ^a,d,e   Sahel, José A ^a,b,i,j   Picaud, Serge ^a,b,j,k,l  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g DOHENY EYE INSTITUTE   (United States)

^h NeuroTherapeutics Pharmaceuticals   (United States)

ⁱ CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^j FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l INSTITUT DE LA VISION   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; TAURINE; VIGABATRIN;

AMINO ACID BLOOD LEVEL; AMINO ACID DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL DENSITY; CELL FUNCTION; CONTROLLED STUDY; DARKNESS; DIETETICS; DRUG EFFECT; ELECTRORETINOGRAM; EYE TOXICITY; FOOD; GLIOSIS; LIGHT EXPOSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; RETINA CELL; RETINA CONE; RETINAL PHOTOTOXICITY; SCREENING; SEIZURE; SUPPLEMENTATION; TAURINE DEFICIENCY; VISUAL FIELD;

EID: 60849124804     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21526     Document Type: Article

References (44)

1. Ben-Menachem E, Dulac O, Chiron C. Vigabatrin. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2008:1683-1693.
2. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
3. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998;116:817-819.
4. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181.
5. Johnson MA, Krauss GL, Miller NR, et al. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000;55:40-45.
6. Hilton EJ, Cubbidge RP, Hosking SL, et al. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia 2002;43:1351-1359.
7. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999;53:2082-2087.
8. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003;61:1690-1694.
9. Buncic JR, Westall CA, Panton CM, et al. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 2004;111:1935-1942.
10. Westall CA, Logan WJ, Smith K, et al. The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin. Doc Ophthalmol 2002;104:133-149.
11. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-395.
12. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005;4:712-717.
13. Dulac O, Dalla Bernardina B, Chiron C. West syndrome. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2008:2329-2335.
14. Snead OC 3rd, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983;33:966-970.
15. Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994;124:803-806.
16. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97:375-379.
17. Gerasimov MR, Dewey SL. Gamma-vinyl gamma-aminobutyric acid attenuates the synergistic elevations of nucleus accumbens dopamine produced by a cocaine/heroin (speedball) challenge. Eur J Pharmacol 1999;380:1-4.
18. Stromberg MF, Mackler SA, Volpicelli JR, et al. The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat. Pharmacol Biochem Behav 2001;68:291-299.
19. Sills GJ, Patsalos PN, Butler E, et al. Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001;57:196-200.
20. Neal MJ, Cunningham JR, Shah MA, Yazulla S. Immunocyto-chemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina. Neurosci Lett 1989;98:29-32.
21. Cubells JF, Blanchard JS, Makman MH. The effects of in vivo inactivation of GABA-transaminase and glutamic acid decarboxylase on levels of GABA in the rat retina. Brain Res 1987;419:208-215.
22. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987;15:143-148.
23. Duboc A, Hanoteau N, Simonutti M, et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004;55:695-705.
24. Wang QP, Jammoul F, Duboc A, et al. Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina. Eur J Neurosci 2008;27:2177-2187.
25. Izumi Y, Ishikawa M, Benz AM, et al. Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. Epilepsia 2004;45:1043-1048.
26. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-1778.
27. Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996;37:638-642.
28. Zhu X, Li A, Brown B, et al. Mouse cone arrestin expression pattern: light induced translocation in cone photoreceptors. Mol Vis 2002;8:462-471.
29. Rapp LM, Thum LA, Anderson RE. Synergism between environmental lighting and taurine depletion in causing photoreceptor cell degeneration. Exp Eye Res 1988;46:229-238.
30. Cocker SE, Lake N. Effects of dark maintenance on retinal biochemistry and function during taurine depletion in the adult rat. Vis Neurosci 1989;3:33-38.
31. Bernasconi R, Klein M, Martin P, et al. Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J Neural Transm 1988;72:213-233.
32. Lyubarsky AL, Daniele LL, Pugh EN Jr. From candelas to photoisomerizations in the mouse eye by rhodopsin bleaching in situ and the light-rearing dependence of the major components of the mouse ERG. Vision Res 2004;44:3235-3251.
33. Leon A, Levick WR, Sarossy MG. Lesion topography and new histological features in feline taurine deficiency retinopathy. Exp Eye Res 1995;61:731-741.
34. Neuringer M, Sturman J. Visual acuity loss in rhesus monkey infants fed a taurine-free human infant formula. J Neurosci Res 1987;18:597-601.
35. Imaki H, Moretz R, Wisniewski H, et al. Retinal degeneration in 3-month-old rhesus monkey infants fed a taurine-free human infant formula. J Neurosci Res 1987;18:602-614.
36. Neal MJ, Shah MA. Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol 1990;100:324-328.
37. Lee NY, Kang YS. The brain-to-blood efflux transport of taurine and changes in the blood-brain barrier transport system by tumor necrosis factor-alpha. Brain Res 2004;1023:141-147.
38. Verrotti A, Manco R, Matricardi S, et al. Antiepileptic drugs and visual function. Pediatr Neurol 2007;36:353-360.
39. Harding GF, Wild JM, Robertson KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000;55:347-352.
40. Bush RA, Sieving PA. A proximal retinal component in the primate photopic ERG a-wave. Invest Ophthalmol Vis Sci 1994;35:635-645.
41. El-Sherbeny A, Naggar H, Miyauchi S, et al. Osmoregulation of taurine transporter function and expression in retinal pigment epithelial, ganglion, and muller cells. Invest Ophthalmol Vis Sci 2004;45:694-701.
42. Gupta RC, Win T, Bittner S. Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 2005;12:2021-2039.
43. Halonen T, Lehtinen M, Pitkanen A, et al. Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res 1988;2:246-252.
44. Pitkanen A, Matilainen R, Ruutiainen T, et al. Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients. J Neurol Neurosurg Psychiatry 1988;51:1395-1400.